Cryo-Cell International, Inc. (CCEL) - Q2 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended May 31, 2025. Cryo-Cell International, Inc. operates in three segments: (1) cellular processing and cryogenic storage of umbilical cord blood and tissue for family use; (2) manufacture of PrepaCyte CB processing units; and (3) public cord blood banking. The Company is headquartered in Oldsmar, Florida, with storage facilities in Durham, North Carolina.
Key Financial Metrics (Six Months Ended May 31, 2025)
- Revenue: $15,897,723 (Flat vs. prior year period of $15,895,046).
- Net Income: $638,640 (Decreased from $1,212,031 in the prior year period).
- Operating Income: $2,548,645 (Increased from $2,212,741).
- Cash Flow from Operations: $1,661,077 (Increased from $1,416,616).
- Cash and Cash Equivalents: $137,491 (Decreased from $560,960 at Nov 30, 2024).
- Marketable Securities: $4,293,513 (Increased from $2,935,183).
- Total Debt: $15,036,582 (Includes $6,620,000 Line of Credit and $8,416,582 Term Note).
- Stockholders' Deficit: $(15,559,805).
Material Changes vs. Prior Period
- Revenue Composition: Processing and storage fees decreased slightly ($15.74M vs $15.77M) due to a 15% drop in new domestic specimens, offset by a 4% increase in recurring storage fees. Public banking revenue increased to $124,767 from $85,190.
- Expenses: Selling, general, and administrative (SG&A) expenses rose 7% to $8.89M. Research and development expenses dropped significantly to $229,854 from $743,974, primarily due to the cessation of funding for the Duke IMPACT Study and related clinical trials.
- Interest Expense: Increased to $1,046,088 from $585,732, driven by higher interest rates and the cessation of interest capitalization on the new facility construction.
- Investment Losses: The Company recorded a loss of $410,733 on marketable securities, compared to a gain of $533,594 in the prior year.
- Dividends: The Company paid $3,231,227 in cash dividends ($0.40 per share total for the six months), compared to $0 in the prior year period.
Guidance, Outlook, and Material Risks
- Duke University Dispute: A critical contingency involves an arbitration demand filed against Duke University regarding the Duke License Agreement. Duke terminated the agreement on May 17, 2025. The Company claims damages exceeding $100 million. Consequently, the planned Cryo-Cell Institute for Cellular Therapies is on pause, and the proposed spinoff of Celle Corp. is on hold.
- Liquidity: Cash on hand decreased significantly due to dividend payments and investing activities. The Company anticipates funding future needs through operations, its revolving line of credit (currently $6.62M utilized of $10M), and potential additional financing.
- Capital Expenditures: The Company anticipates discretionary capital expenditures of approximately $5 million over the next 12 months for facility build-outs and equipment.
- Legal Proceedings: Aside from the Duke dispute, the Company is involved in a class action lawsuit (Lindsey Lehr v. Cryo-Cell) regarding advertising claims, with a final hearing scheduled for September 2025.
Investor Verification Checklist
- Verify the status and potential financial impact of the Duke University arbitration and the termination of the License Agreement.
- Confirm the Company's ability to service its debt obligations given the reduced cash balance and increased interest expense.
- Assess the sustainability of the dividend policy ($0.40/share paid in six months) against the current cash burn and operating cash flow.
- Monitor the decline in new domestic cord blood specimen enrollments (down 15% YoY) and its long-term impact on recurring revenue growth.
- Review the valuation of the $4.3M in marketable securities and the associated unrealized losses.